FDA Approves Simtriyo (centanafadine) for the Treatment of Attention-Deficit Hyperactivity Disorder (ADHD)
NDA FilingapprovedSimtriyoPositive
AI Analysis
Summary
FDA has approved Simtriyo (centanafadine), developed by Otsuka Pharmaceutical, for the treatment of Attention-Deficit Hyperactivity Disorder (ADHD).
Outcome Details
FDA approval granted for Simtriyo (centanafadine) for ADHD treatment
Importance:8/10
Sentiment:
0.95
FDA approvalADHDNDAcentanafadineOtsuka
Read the original article
Published by Drugs.com New Drug Approvals on July 24, 2026 11:07 PM